ClinConnect ClinConnect Logo
Search / Trial NCT03077633

Cerclage for Twins With Short Cervix

Launched by PEDIATRIX · Mar 10, 2017

Trial Information

Current as of August 02, 2025

Withdrawn

Keywords

Cerclage Cervical Shortening Twins Progesterone

ClinConnect Summary

A prospective Randomized Trial that will test whether treatment with cervical cerclage plus vaginal progesterone improves pregnancy outcomes among women with twin pregnancy at 16 0/7 to 25 6/7 weeks of gestation who have a cervical length (CL) of 0.1 to 15.0 mm on transvaginal ultrasound exam, the rate of preterm birth at less than 32 weeks of gestation (PTB\<32 wks.) and the rate of adverse perinatal outcome will be lower in those treated with cervical cerclage plus vaginal progesterone than in those treated with vaginal progesterone alone.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Twin pregnancy (see Exclusion Criterion (a) below re: monochorionic twins)
  • Gestational age 16 0/7 to 25 6/7 weeks at time of enrollment by best-estimated age.
  • Cervical length 0.1 to 15.0 mm on transvaginal ultrasound examination. (Cervical length is taken to mean the length of the closed portion of the cervical canal.
  • Exclusion Criteria:
  • Maternal age less than 18 years
  • Monochorionic twins (such as monochorionic-diamniotic, monochorionic-monoamniotic, or conjoined twins)
  • Rupture of membranes, either twin
  • One or both twins has no cardiac activity
  • One or both twins has known or suspected major malformation, aneuploidy, or polyhydramnios
  • Maternal congenital uterine anomaly (such as bicornuate uterus, unicornuate uterus)
  • Pregnancy started as triplets or higher-order multifetal gestation and then reduced to twins, either spontaneously or via procedure
  • Symptomatic uterine contractions, 6 or more per hour
  • Ongoing bleeding from uterus
  • Patient declines to consider cerclage
  • Patient declines treatment with vaginal progesterone
  • Allergy to progesterone or peanuts (because the vaginal progesterone formulation used will be a capsule of micronized progesterone in peanut oil.)
  • Cerclage is already in place
  • Cerclage placement is judged to be technically impossible
  • Patient has a history of poor follow-up or poor adherence to physician recommendations
  • Patient is planning to relocate outside the local area before the end of pregnancy such that delivery records will be unavailable
  • Patient does not give consent to participate in this trial.

About Pediatrix

Pediatrix is a leading healthcare organization dedicated to improving the health and well-being of infants, children, and expectant mothers through innovative clinical research and high-quality medical care. With a focus on pediatric specialty services, Pediatrix conducts clinical trials to advance the understanding and treatment of various pediatric conditions, ensuring the integration of evidence-based practices into their patient care. Their commitment to pediatric health is reflected in their collaborative approach with healthcare professionals, researchers, and families, aiming to enhance outcomes and provide a brighter future for young patients.

Locations

Patients applied

0 patients applied

Trial Officials

Andrew Combs, MD

Principal Investigator

Pediatrix

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials